Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression

Annals of Internal Medicine

Volumn 134, Issue 11, 2001, Pages 1033-1042

  Levy, Jeremy B ^a   Turner, A Neil ^b   Rees, Andrew J ^c   Pusey, Charles D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY DISEASE; GOODPASTURE SYNDROME; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0035811228     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-11-200106050-00009     Document Type: Article

References (26)

1. Levy JB, Pusey CD. Anti-GBM antibody mediated disease. In: Wilkinson R, Jamison RL, eds. Nephrology. London: Chapman & Hall; 1997:599-615.
2. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973;3:74-89. [PMID: 4571918]
3. Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967;126:989-1004. [PMID: 4964566]
4. Saus J, Wieslander J, Langeveld JP, Quinones S, Hudson BG. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem. 1988;263:13374-80. [PMID: 3417661]
5. Turner N, Mason PJ, Brown R, Fox M, Povey S, Rees A, et al. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest. 1992;89:592-601. [PMID: 1737849]
6. Hellmark T, Burkhardt H, Wieslander J. Goodpasture disease. Characterization of a single conformational epitope as the target of pathogenic autoantibodies. J Biol Chem. 1999;274:25862-8. [PMID: 10464328]
7. Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet. 1976;1:711-5. [PMID: 56532]
8. Peters DK, Rees AJ, Lockwood CM, Pusey CD. Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc. 1982;14: 513-21. [PMID: 7179435]
9. Herody M, Bobrie G, Gouarin C, Grünfeld J, Noel L. Anti-GBM disease: predictive value of clinical, histological and serological data. Clin Nephrol. 1993; 40:249-55. [PMID: 8281713]
10. Merkel F, Pullig O, Marx M, Netzer KO, Weber M. Course and prognosis of anti-basement membrane antibody (ami-BM-Ab)-mediated disease: report of 35 cases. Nephrol Dial Transplant. 1994;9:372-6. [PMID: 8084449]
11. Savage CO, Pusey CD, Bowman C, Rees AJ, Lockwood CM. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed). 1986;292:301-4. [PMID: 3080145]
12. Daly C, Conlon PJ, Medwar W, Walshe JJ. Characteristics and outcome of anti-glomerular basement membrane disease: a single-center experience. Ren Fail. 1996;18:105-12. [PMID: 8820507]
13. Levy JB, Lachmann RH, Pusey CD. Recurrent Goodpasture's disease. Am J Kidney Dis. 1996;27:573-8. [PMID: 8678069]
14. Katbamna I, Turner N, Ross CN, Pusey CD. Development and application of an ELISA for Goodpasture's disease based on sheep alpha 3(IV)NC1 domains. J Clin Lab Immunol. 1995;47:11-24. [PMID: 8735432]
15. Ewan PW, Jones HA, Rhodes CG, Hughes JM. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in Goodpasture's syndrome. N Engl J Med. 1976;295:1391-6. [PMID: 980094]
16. Rees AJ, Lockwood AM, Peters DK. Enhanced allergic tissue injury in Goodpasture's syndrome by intercurrent bacterial infection. Br Med J. 1977;2: 723-6. [PMID: 912270]
17. Lockwood CM, Boulton-Jones JM, Lowenthal RM, Simpson IJ, Peters DK. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J. 1975;2:252-4. [PMID: 1131574]
18. Bouget J, Le Pogamp P, Perrier G, Ramée MP, Rivalan J, Camus C, et al. [Ann-basement-membrane antibody mediated, rapidly progressive, glomerulonephritis. Diagnostic and therapeutic strategy based on a retrospective study of 14 cases). Ann Med Interne (Paris). 1990;141:409-15. [PMID: 2256583]
19. Johnson JP, Moore JJ, Austin HJ, Blalow JE, Antonovych TT, Wilson CB. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore). 1985;64:219-27. [PMID: 3892220]
20. Walker RG, Scheinkestel C, Becker GJ, Owen JE, Dowling JP, KincaidSmith P. Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome. Q J Med. 1985;54:75-89. [PMID: 3975346]
21. Briggs WA, Johnson JP, Teichman S, Yeager H, Wilson C. Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome. Medicine (Baltimore). 1979;58:348-61. [PMID: 384140]
22. Simpson IJ, Doak PB, Williams LC, Blacklock H, Hill R, Teague C, et al. Plasma exchange in Goodpasture's syndrome. Am ] Nephrol. 1982;2:301-11. [PMID: 6762091]
23. Andrews PA, Sheerin NS, Hicks JA, Williams DG, Sacks SH. Unusual presentations of anti-glomerular basement membrane antibody mediated disease are associated with delayed diagnosis and poor outcome. Clin Nephrol. 1995;44: 262-5. [PMID: 8575127]
24. Bolton WK, Sturgill BC. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol. 1989;9:368-75. [PMID: 2801784]
25. Bolton WK Goodpasture's syndrome. Kidney Int. 1996;50:1753-66. [PMID: 8914046]
26. Levy JB, Pusey CD. Plasmapheresis. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. New York: Mosby; 2000.